Palo Alto, CA – September 7, 2017 – doc.ai, an advanced natural language processing technology platform for quantified biology, today announced the successful completion of its initial sale of Simple Agreements for Future Tokens (“SAFTs”). A total of ten purchasers acquired SAFTs, consisting of institutional and other accredited investors, for an aggregate purchase amount of approximately $2.3 million.
The early pre-sale of doc.ai’s SAFTs, which are convertible into digital tokens named Neurons (“NRNs”), was limited to existing investors and advisors who have either helped support doc.ai in the past, or have demonstrated the desire to partner and support the Neuron Network. Pantera Capital anchored the offering as the lead investor.
“We are excited to be the lead investor in the early SAFT offering by doc.ai”, said Paul Veradittakit, Partner at Pantera Capital. “The company offers an unparalleled innovative technology solution at the intersection of blockchain and artificial intelligence”.
Anthony Di Iorio, Co-Founder of Ethereum and Founder & CEO of Jaxx, who participated in the early pre-sale, commented: “I am amazed by the potential that doc.ai technology has for millions of people all over the world and possible network effects of the NRN token. I am looking forward to exploring potential synergies between doc.ai and Jaxx”.
“The initial pre-sale demonstrates for doc.ai the confidence of these investors,” commented doc.ai founder and chief executive officer Walter De Brouwer. “We believe that artificial intelligence is poised to revolutionize healthcare and drastically improve patients’ care and experience, and our investors have proven their adherence to our vision.”
The pre- sale to eligible investors of SAFTs to acquire doc.ai’s Neuron (NRN) tokens, based on the ERC-20 standard, commences on September 7, 2017. The crowdsale process is expected to start on September 28, 2017. The solicitation, offer, and sale of SAFTs in all phases will be conducted in a manner that is compliant with applicable securities laws and regulations, including Rule 506(c) of Regulation D. In the United States, only verified accredited investors will be eligible to purchase SAFTs.
For more information visit tokensale.doc.ai.
About DOC.AI
doc.ai is helping healthcare companies to improve patients’ care and experience by creating the industry’s most advanced intelligent natural language processing platform that generates insights from medical data. doc.ai’s team is teaching machines the language of biology and training the first generation of AI in natural language comprehension and computer vision. doc.ai was founded by the entrepreneurial duo Walter and Sam De Brouwer in 2016. The Palo Alto, California, company has raised seed funding from Comet Labs, F50, Legend Star and S2 Capital, and has several prominent clients.
Forward Looking Statements
Certain information set forth in this press release contains “forward-looking information” under applicable securities laws. Except for statements of historical fact, information contained herein constitutes forward-looking statements and includes, but is not limited to, (i) the projected performance of doc.ai; (ii) the completion of, and the use of proceeds from, the sale of SAFTs; (iii) the expected development of doc.ai’s business, projects, and joint ventures; (iv) the execution of the Company’s vision and growth strategy, including with respect to future global growth; (v) the sources and availability of third-party financing for doc.ai’s projects; (vi) the completion of doc.ai’s projects that are currently underway, in development or otherwise under consideration; (vii) doc.ai’s ability to launch a functional platform, which includes the related creation and issuance of NRNs; (viii) renewal of the Company’s current customer, supplier, and other material agreements; and (ix) the future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential purchasers of SAFTs the opportunity to understand management’s beliefs and opinions in respect of the future. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements. Although forward-looking statements contained in this press release are based upon what management believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. doc.ai’s undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change, except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
Securities Disclaimer
This press release is for informational purposes only and does not constitute an offer or solicitation to sell securities. Any such offer or solicitation will be made only by means that are in compliance with applicable securities and other laws, including Rule 506(c) of Regulation D. No information or opinions presented herein are intended to form the basis for any purchase decision, and no specific recommendations are intended. Accordingly, this press release does not constitute investment advice or counsel or solicitation for investment in any security. This press release does not constitute or form part of, and should not be construed as, any offer for sale or subscription of, or any invitation to offer to buy or subscribe for, any securities, nor should it or any part of it form the basis of, or be relied on in any connection with, any contract or commitment whatsoever. doc.ai expressly disclaims any and all responsibility for any direct or consequential loss or damage of any kind whatsoever arising directly or indirectly from: (i) reliance on any information contained in this press release, (ii) any error, omission or inaccuracy in any such information, and (iii) any action resulting therefrom
